Methodological approaches of clinical studies with targeted therapies;Particularités méthodologiques des études cliniques appliquées à l'évaluation des thérapeutiques ciblées

Bulletin du Cancer

Volumn 95, Issue 2, 2008, Pages 185-190

  Penel, Nicolas ^a,b   Saleron, Julia ^b,c   Lansiaux, Amélie ^a   Clisant, Stéphanie ^a   Adenis, Antoine ^a   Fournier, Charles ^a   Duhamel, Alain ^b,c   Bonneterre, Jacques ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

^c Faculté de Médecine Pôle Recherché   (France)

Author keywords

Biomarkers; Methodology; Phase II; Targeted therapie

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC AGENT; ERLOTINIB; IMATINIB; IMMUNOSTIMULATING AGENT; METALLOPROTEINASE INHIBITOR; PLACEBO;

BIOLOGICAL ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG TARGETING; DRUG TOLERABILITY; EXPERIMENTAL DESIGN; HUMAN; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WITHHOLDING TREATMENT;

EID: 40349105988     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0575     Document Type: Review

References (54)